Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.

2.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

3.

Falling asleep at the wheel and distracted driving. The High-Risk Professional Drivers study.

Rosso GL, Candura S, Perotto M, Caramella M, Montomoli C.

Med Lav. 2018 Mar 27;109(3):190-200. doi: 10.23749/mdl.v109i3.6731.

PMID:
29943750
4.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
5.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

6.

Pier Diego Siccardi (1880-1917) and the "Clinica del Lavoro" in the trench warfare.

Riva MA, Caramella M, Turato M, Cesana G.

Med Lav. 2017 Dec 14;108(6):482-486. doi: 10.23749/mdl.v108i6.6227.

PMID:
29240045
7.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
8.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.

Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. No abstract available.

PMID:
27885272
9.

Investigating obesity among professional drivers: the high risk professional driver study.

Rosso GL, Perotto M, Feola M, Bruno G, Caramella M.

Am J Ind Med. 2015 Feb;58(2):212-9. doi: 10.1002/ajim.22400.

PMID:
25603943
10.

Falling asleep at the wheel among Italian professional drivers (PDs): results from the HiRis PD study.

Rosso GL, Perotto M, Feola M, Caramella M.

Int J Occup Med Environ Health. 2014 Dec;27(6):1005-12. doi: 10.2478/s13382-014-0327-z. Epub 2014 Dec 10.

11.

Workplace drug testing and alcohol policy in Italy; there is still a long way to go.

Rosso GL, Perotto M, Feola M, Caramella M.

Drug Test Anal. 2014 Sep;6(9):893-7. doi: 10.1002/dta.1569. Epub 2013 Oct 25.

PMID:
24166787
12.

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A.

Blood. 2010 Mar 4;115(9):1703-8. doi: 10.1182/blood-2009-09-245837. Epub 2009 Dec 14.

13.

Fluid loss does not explain coagulation activation during air travel.

Schreijer AJ, Cannegieter SC, Caramella M, Meijers JC, Krediet RT, Simons RM, Rosendaal FR.

Thromb Haemost. 2008 Jun;99(6):1053-9. doi: 10.1160/TH07-11-0681.

PMID:
18521508
14.

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, Del Curto C, Pietra D, Vanelli L, Bernasconi P, Pascutto C, Cazzola M, Morra E, Lazzarino M.

Blood. 2008 Apr 1;111(7):3383-7. doi: 10.1182/blood-2007-11-121434. Epub 2008 Jan 10.

15.

Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.

Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, Gatti M, Gargantini L, Caramella M, Mancini V, Gerna G, Morra E; Co-operative Study Group on PTLDs.

Br J Haematol. 2003 Sep;122(6):927-33. Review.

PMID:
12956763

Supplemental Content

Loading ...
Support Center